Advanced Maxillary Sinus Cancer Treated with Concurrent Chemoradiotherapy with Intra-Arterial Cisplatin/Docetaxel and Oral S-1: Own Experience and Literature Review by Nakashima, Torahiko et al.
Case Rep Oncol 2011;4:492–498 
DOI: 10.1159/000332759 
Published online: 
October 3, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online
version of the article only. Distribution for non-commercial purposes only. 
 
 
Torahiko Nakashima, MD    Department of Otolaryngology-Head and Neck Surgery 
Graduate School of Medical Sciences, Kyushu University 
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan) 
Tel. +81 92 642 5668, E-Mail nakatora @ qent.med.kyushu-u.ac.jp 
 
492
   
Advanced Maxillary Sinus 
Cancer Treated with Concurrent 
Chemoradiotherapy with Intra-
Arterial Cisplatin/Docetaxel and 
Oral S-1: Own Experience and 
Literature Review 
Torahiko Nakashimaa    Ryuji Yasumatsua    Satoshi Toha    
Hideki Shiratsuchia    Takeshi Kamitanib    
Yoshiyuki Shioyama
c    Katsumasa Nakamurab    
Shizuo Komune
a 
Departments of aOtolaryngology-Head and Neck Surgery, bClinical Radiology and 
cHeavy Particle Therapy and Radiation Oncology, Graduate School of Medical 
Sciences, Kyushu University, Fukuoka, Japan 
 
 
Key Words 
Head and neck cancer · Intra-arterial chemoradiotherapy · Cisplatin · Docetaxel · S-1 
 
Abstract 
Intra-arterial (IA) chemotherapy for head and neck cancer is effective and multiple IA 
concurrent chemoradiation (CCRT) protocols have been reported. However, the role of IA 
CCRT in the multimodality treatment of head and neck cancer is still controversial. We 
have treated 5 cases of unresectable T4 maxillary sinus squamous cell carcinoma with IA 
cisplatin (CDDP) and docetaxel (DOC) and CCRT with oral S-1. We report our experience 
and the effectiveness and feasibility of this combination as an alternative choice of 
treatment for inoperable head and neck cancer. The patients received an IA infusion of 
CDDP (50–70 mg/m2) and DOC (50–60 mg/m2) through the femoral artery, followed by 
CCRT with oral S-1. The IA infusion was repeated up to 3 times and the radiation was 
dosed at up to 60–70 Gy. Complete response was achieved in 4 patients and partial 
response in one, giving an overall response rate of 100%. The most common grade 3 or 4 
toxicities were anorexia (80%), mucositis (80%) and leukopenia (80%), all of which were 
manageable. CCRT with IA CDDP/DOC and oral S-1 was effective and tolerated. Although 
preliminary, the response rate encourages further pursuit and definitive evaluation of 
this combination for the treatment of inoperable advanced head and neck cancer. 
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Introduction 
Owing to the development of interventional radiological techniques, intra-arterial (IA) 
chemotherapy for treating head and neck cancer is nowadays widely used and has been 
studied and evaluated in many institutions. Protocols combining IA chemotherapy with 
concurrent radiotherapy demonstrated high organ preservation rates in locally advanced 
head and neck cancer. Multiple trials, particularly those using high-dose cisplatin 
(CDDP) (RADPLAT) have been reported to show a high response rate [1, 2]. However, 
the feasibility and the effectiveness of the RADPLAT protocol are still controversial [3, 4]. 
Docetaxel (DOC) is commonly used in concurrent chemoradiotherapy (CCRT) for 
head and neck cancer [5–7]. IA chemotherapy combining DOC and CDDP has also 
previously been reported to be effective in treating head and neck cancer [8, 9]. 
S-1 is an oral fluorouracil anticancer agent consisting of tegafur, 5-chloro-2,4 
dihydropyridine, which inhibits dihydropyrimidine dehydrogenase enzyme activity, and 
oteracil (potassium oxonate) as an inhibitor of gastrointestinal side effects [10]. In our 
institution, CCRT using S-1 and retinyl palmitate has been used for treating head and 
neck cancer to pursue the possibility of organ preservation [11, 12]. In the present study 
on treating locally advanced unresectable maxillary sinus cancer, IA infusion of CDDP 
and DOC was added to the regular CCRT with S-1 to maximize the local effect of the 
CCRT. The aim of this paper is to describe our experience and the effectiveness and 
feasibility of the combination of IA CDDP, DOC and CCRT with oral S-1 in the 
treatment of highly advanced maxillary sinus cancer. 
Patients and Methods 
Between July 2007 and March 2008, 5 patients (3 men, 2 women) with unresectable T4 squamous 
cell carcinoma of the maxillary sinus (including one patient refusing radical operation) underwent our 
IA CCRT protocol. Eligible patients were aged <75 years with a performance status of 0 to 1 (table 1). 
All patients were fully informed about the treatment protocol and written informed consent was 
obtained.  
IA Chemotherapy 
The femoral artery was punctured under local anesthesia by Seldinger’s method. The tip of the 
catheter was threaded into the external carotid artery. Fluorography was performed through a micro-
catheter to determine the dominant tumor-supplying vessel with digital angiography. Cone-beam 
computed tomography was also used during angiography to ascertain the stained area. In cases which 
had multiple tumor-supplying vessels, the dose of CDDP and DOC was divided according to the stained 
tumor volume. 
IA infusion of CDDP (50–70 mg/m
2) and DOC (50–60 mg/m
2) was administered through the 
micro-catheter on day 1 (fig. 1). The doses of the agents were determined mainly depending on the 
patients’ residual renal and bone marrow functions. A 5-HT3-receptor antagonist was also given to all 
patients to reduce nausea/vomiting. For patients who were judged to need multiple courses of 
chemotherapy, IA infusion was repeated up to 3 times in intervals of 4–6 weeks. Depending on the 
general conditions of the 5 patients, 2 patients received an IA infusion once, 2 patients twice and one 
patient 3 times (table 1). Case Rep Oncol 2011;4:492–498 
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Radiotherapy with S-1 
Three-dimensional conformal radiotherapy was performed to the primary sites and regional cervical 
lymph node areas through a linear accelerator with a 4-MV X-ray. The start of radiotherapy ranged 
from day 3 to day 7 depending on the general condition of the patient. Conventional fractionation was 
used with a daily dose of 1.8–2.0 Gy, 5 times a week up to a total dose of 60–70 Gy (fig. 1). S-1 was 
concurrently administered to the patients orally twice daily at an initial dose of 65 mg/m
2/day [patients 
with a body surface area (BSA) >1.5 m
2 received 100 mg/day, patients with 1.25 m
2 < BSA < 1.5 m
2 
received 80 mg/day, and patients with a BSA <1.25 m
2 received 50 mg/day]. Patients with renal 
dysfunction received a 60–80% reduced dose of S-1. Retinyl palmitate (50,000 U/day) was also 
administered intra-muscularly on each day of radiation as an adjuvant for CCRT. S-1 administration 
was stopped if grade IV toxicity (leukopenia) due to the IA chemotherapy appeared. 
Evaluation of Response and Toxicity 
Clinical responses of the CRT were evaluated by inspection, fiberscope examination, CT, and MRI 4 
weeks after completion of therapy and FDG-PET was performed 8–10 weeks after completion. 
All toxicities due to the protocol were evaluated according to the National Cancer Institute-
Common Toxicity Criteria (ver. 4.0). 
Results 
Clinical Response 
Five patients with locally advanced maxillary sinus cancer were treated according to 
our protocol and were evaluated. All patients required hospitalization for intensive care. 
Their ages ranged from 37 to 67 years. Four patients were considered to have functionally 
unresectable disease and 1 patient refused surgery. Histologically, all cases were squamous 
cell carcinoma. Patients’ characteristics and results are listed in table 1. The median 
follow-up duration was 24 months (range 22–36). Of the 5 patients, 4 had a complete 
response (fig. 2) and one had a partial response, resulting in an overall response rate of 
100%. In one case with partial response in the primary region, systemic chemotherapy 
was given.  
Toxicity (table 2) 
Table 2 shows the major adverse events during therapy. The most common grade 3 or 
4 toxicities were anorexia, mucositis and leukopenia, all of which were manageable. 
Treatment was temporarily suspended in 3 cases due to the toxicity (febrile neutropenia); 
however, all patients recovered within 10 days. There was one case with grade 4 colitis 
which was suspected to be a side effect of DOC and S-1.  
Discussion 
IA chemotherapy has been reported to be suitable for head and neck cancer therapy 
because of its easy access to the arterial system. Multiple IA chemoradiation protocols 
have been reported for head and neck cancer treatment, among which RADPLAT has Case Rep Oncol 2011;4:492–498 
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been studied most widely [1, 2]. Robbins et al. [2] reported the feasibility and the 
effectiveness of the RADPLAT protocol in a multi-institutional setting. However, in 2010, 
Rasch et al. [3] reported that RADPLAT was not superior to intravenous chemoradiation 
for advanced head and neck cancer patients regarding locoregional control and survival. 
The effectiveness of IA chemoradiation in the treatment of locally advanced head and 
neck cancer is still controversial. 
For patients who have unresectable (T4b) disease or who refuse to receive radical 
operation, CCRT is the current standard therapy. However, it is still difficult to control 
highly advanced disease by conventional intravenous CCRT protocols. IA infusion allows 
exposure of the tumor tissue to a high concentration of chemotherapeutic agents. The 
effectiveness of chemoradiation for highly advanced locoregional disease is maximized if 
IA CCRT protocols are used in an appropriate patient setting. 
Our IA chemoradiation protocol using IA infusion of DOC and CDDP and oral S-1 
revealed a high locoregional effect in patients with unresectable head and neck cancer. 
The combination of DOC and CDDP has been applied to the treatment of multiple 
cancer types including head and neck cancer [9, 13]. The advantage of this regimen is that 
the combination of DOC and CDDP has a synergistic anti-cancer effect of the G2 cell 
cycle arrest caused by DOC and the G1 cell cycle arrest caused by CDDP. DOC has also 
been reported to enhance the cytotoxicity of CDDP to cancer cells by modifying 
intracellular platinum metabolism [14]. Using a regular dose of CDDP instead of a single 
high dose, neutralization of the systemic flow of the agents, which is needed in the 
RADPLAT protocol, becomes superfluous. Additionally, a systemic effect targeting 
subclinical metastasis can be expected. 
Grade 3–4 acute toxicity was observed in 80% of the patients. The incidence of 
leukopenia and mucositis was high and therefore careful management is necessary. 
Although not so frequent, colitis due to DOC infusion is an important side effect which 
should be noted. Kreis et al. [15] first reported on neutropenic enterocolitis. With the 
combination with S-1, which is another enterotoxic agent, gastroenterological toxicities 
should be meticulously observed.  
Since the report by Rasch et al. [3], the efficacy of IA chemoradiation for head and 
neck cancer has been questioned. However, we believe that if technical procedures and 
protocols are improved, IA CCRT is still an effective method for a certain group of 
patients. Although feasibility was proved, the incidence of toxic events, mainly 
hematologic, was high and our protocol may not be suitable as a standard therapy. 
However, the response rate encourages further pursuit and definitive evaluation of this 
combination for treating locally highly advanced unresectable head and neck 
malignancies. 
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Table 1. Patients’ characteristics and results 
Patient 
No. 
Age/ 
gender 
T N IA 
infusions 
(n) 
Results Treatment 
followed 
Survival  
period 
Alive at present 
1 45/F  4b  2b  3 CR    36  months  yes 
2 67/M  4a  2b  2 PR  chemotherapy  27  months  unknown 
3 37/M  4b  0  1 CR    26  months  yes 
4 62/M  4b  2b  2 CR    22  months  yes 
5 61/F  4a  0  1 CR    22  months  yes 
 
 
Table 2. Incidence of major acute toxicity (≥grade 3) 
Mucositis 4  (80%) 
Leukopenia 4  (80%) 
Nausea/vomiting 1  (20%) 
Diarrhea 1  (20%) 
Anorexia 3  (60%) 
 
 
 
 
 
Fig. 1. Treatment schedule for chemoradiotherapy using IA infusion. 
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Fig. 2. Squamous cell carcinoma of the left maxillary sinus (case No. 1: T4aN0M0). Enhanced CT scan 
(a coronal view; b sagittal view) shows a tumor in the left maxillary sinus extending to the orbital apex. 
After treatment, clinical CR was obtained (c coronal view; b sagittal view). 
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